RecruitingPhase 1NCT07299084

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus


Sponsor

Eli Lilly and Company

Enrollment

40 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how the length of fasting before a procedure, and whether a weight-loss medication called tirzepatide is paused beforehand, affects how much food and liquid remains in the stomach — which is important for anesthesia safety. **You may be eligible if...** - You have type 2 diabetes, OR - You have obesity, OR - You are overweight with at least one related health condition (but do not have type 2 diabetes) **You may NOT be eligible if...** - You have a condition that affects how your stomach empties (such as gastroparesis) - You have had weight loss surgery in the past - You have type 1 diabetes - You have other major medical conditions or histories that could affect the study results Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTirzepatide

Administered SC


Locations(1)

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07299084


Related Trials